INFORMATION DISCLOSURE STATEMENT

Complete if known
Application Number: 09/870379
Filing Date: May 30, 2001
First Named Inventor: Donald L. Durden
Group Art Unit: 1642
Examiner Name: Yu, Misook
Attorney Docket Number: 1857-P02575US1

SHEET 1 OF 1

UNITED STATES PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	6020199	02-01-2000	Monia, et al.

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT

OTHER PRIOR ART - NON-PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C1	LI, DA-MING, et al., "PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G_1 cell cycle arrest in human glioblastoma cells"; Proc. Natl. Acad. Sci. USA, 95:15406-15411 (1998)
	C2	LI, LIWU, et al., "A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast"; J. Biological Chemistry, 272: 29403-29406 (1997)
	C3	LI, JING, et al., "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer"; Science 275: 1943-1947 (1997)
	C4	HUANG, HE, et al., "PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development"; Development 126: 5365-5372 (1999)
	C5	LEE, JIE-OH, et al., "Crystal Structure of the PTEN Tumor Suppressor: Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association"; Cell, 99: 323-334 (1999)
	C6	SUN, HONG, et al., "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5 -trisphosphate and Akt/protein kinase B signaling pathway"; Proc. Natl. Acad. Sci. USA 96: 6199-6204 (1999)
	C7	GIRI, D., et al., "Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma"; PubMed, Hum. Pathol. 30:419-24 [abstract] (1999)

EXAMINER'S SIGNATURE		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.